Literature DB >> 29462597

Validity and Reliability of Outcome Measures Assessing Dexterity, Coordination, and Upper Limb Strength in Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay.

Cynthia Gagnon1, Isabelle Lessard2, Bernard Brais3, Isabelle Côté4, Caroline Lavoie4, Matthis Synofzik5, Jean Mathieu4.   

Abstract

OBJECTIVE: To document in adults affected by autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) the intra- and interrater reliability, standard error of measurement, agreement, minimal detectable change, and construct validity of the 9-Hole Peg Test (NHPT), the Standardized Finger-to-Nose Test (SFNT), and grip strength.
DESIGN: Metrologic study.
SETTING: Neuromuscular rehabilitation clinic. PARTICIPANTS: Genetically confirmed adult patients with ARSACS (N=42; 21 women; mean age, 38.6y).
INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: Intra- and interrater reliability was determined using the intraclass correlation coefficient (ICC). Construct validity was determined by assessing the capacity of the NHPT, the SFNT, and grip strength to distinguish between participants based on sex, mobility stages, and age groups, and on performance on the Archimedes spiral and fast alternating hand movements tests.
RESULTS: All 3 tests have shown excellent reliability (ICC=.90-.98). However, the limit of agreement was influenced by the participant's performance on the NHPT, and the minimal detectable change was very different for both hands (right=9.7 vs left=28.0). Construct validity was confirmed for the SFNT and NHPT, but it was not demonstrated for grip strength.
CONCLUSIONS: Given the metrologic properties assessed in this study, the SFNT is an excellent measure to assess upper limb coordination, whereas the NHPT must be used with caution. The grip strength is reliable but does not seem to reflect disease severity.
Copyright © 2017 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Outcome assessment (health care); Rehabilitation; Reproducibility of results; Spastic ataxia Charlevoix-Saguenay type; Validation studies

Mesh:

Year:  2018        PMID: 29462597     DOI: 10.1016/j.apmr.2018.01.026

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  6 in total

1.  Development and validation of a disease severity index for ataxia of Charlevoix-Saguenay.

Authors:  Cynthia Gagnon; Bernard Brais; Isabelle Lessard; Caroline Lavoie; Isabelle Côté; Jean Mathieu
Journal:  Neurology       Date:  2019-09-18       Impact factor: 9.910

2.  An exploratory natural history of ataxia of Charlevoix-Saguenay: A 2-year follow-up.

Authors:  Cynthia Gagnon; Isabelle Lessard; Caroline Lavoie; Isabelle Côté; Raphaël St-Gelais; Jean Mathieu; Bernard Brais
Journal:  Neurology       Date:  2018-08-29       Impact factor: 9.910

3.  Assessment of the impact of an exercise program on the physical and functional capacity in patients with autosomal recessive spastic ataxia of Charlevoix-Saguenay: An exploratory study.

Authors:  Olivier Audet; Hung Tien Bui; Maxime Allisse; Alain-Steve Comtois; Mario Leone
Journal:  Intractable Rare Dis Res       Date:  2018-08

4.  From motor performance to participation: a quantitative descriptive study in adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay.

Authors:  Cynthia Gagnon; Bernard Brais; Isabelle Lessard; Caroline Lavoie; Isabelle Côté; Jean Mathieu
Journal:  Orphanet J Rare Dis       Date:  2018-09-19       Impact factor: 4.123

5.  Upper Body Physical Rehabilitation for Children with Ataxia through IMU-Based Exergame.

Authors:  Alberto Romano; Martina Favetta; Susanna Summa; Tommaso Schirinzi; Enrico Silvio Bertini; Enrico Castelli; Gessica Vasco; Maurizio Petrarca
Journal:  J Clin Med       Date:  2022-02-18       Impact factor: 4.241

Review 6.  Documenting manifestations and impacts of autosomal recessive spastic ataxia of Charlevoix-Saguenay to develop patient-reported outcome.

Authors:  Marjolaine Tremblay; Laura Girard-Côté; Bernard Brais; Cynthia Gagnon
Journal:  Orphanet J Rare Dis       Date:  2022-10-01       Impact factor: 4.303

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.